Skip to main content
All lobbying filings

MEHLMAN CONSULTING, INC.

MEHLMAN CONSULTING, INC. filed a Q3 report for ASSOCIATION OF ACCESSIBLE MEDICINES on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES · Trade Association

All filings by MEHLMAN CONSULTING, INC. · Everything ASSOCIATION OF ACCESSIBLE MEDICINES has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • SEAN BRADY New on this filing
    Previously held: Dir Leg Affairs (DOC, Intl Trade Admin); CoS, Dep. CoS/ LD, SLA, LA, Staff Asst (Rep. Vern Buchanan); Intern (Rep. Fred Upton); Intern (Rep. Dan Lungren)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Issues related to generic medicines.

Health Issues

Issues related to generic and biosimilar medications.

Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling. H.R. 9661/S. 1414 - Expediated Access to Biosimilars Act.

 Bills named in this filing 9
  • S. 1040
    Drug Competition Enhancement Act
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • H.R. 3269
    ETHIC Act
  • S. 43
    Skinny Labels, Big Savings Act
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
  • H.R. 9661
    Expedited Access to Biosimilars Act
  • S. 1414
    Expedited Access to Biosimilars Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem